Most Read Articles
3 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
2 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 6 days ago
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).

Electrical nerve stimulation helps mitigate movement-evoked pain in fibromyalgia

12 Jan 2020

Use of active transcutaneous electrical nerve stimulation (TENS) in fibromyalgia (FM) patients receiving treatment results in a favourable reduction in movement-evoked pain, according to the results of a trial.

The trial randomized female FM patients receiving steady medication to active TENS (n=103), placebo TENS (n=99) or no TENS (n=99). TENS was applied to the lumbar and cervicothoracic regions using a modulated frequency (2–125Hz) at the highest tolerable intensity, with patients instructed to use it at home 2h/day during activity for 4 weeks.

Movement‐evoked pain (primary outcome) and fatigue were rated on an 11‐point scale before and during application of TENS.

After 4 weeks, movement-evoked pain decreased significantly with active TENS vs placebo TENS (mean difference, –1.0, 95 percent confidence interval [CI], –1.8 to –0.2; p=0.008) and no TENS (mean difference, –1.8, 95 percent CI, –2.6 to –1.0; p<0.0001). The same was observed for fatigue (mean difference, –1.4, 95 percent CI, –2.4 to –0.4; p=0.001 and mean difference, –1.9, 95 percent CI, –2.9 to –0.9; p=0.0001, respectively).

Significantly more patients in the active‐TENS group reported improvement in the global impression of change than in the placebo‐TENS and no-TENS groups (70 percent vs 31 percent and 9 percent, respectively; p-both<0.0001).

There were no reports of TENS‐related serious adverse events, with <5 percent of the overall population experiencing minor adverse events with TENS.

Additional investigation is warranted to examine effectiveness in a real world, pragmatic setting to establish clinical importance of the present data, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
2 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 6 days ago
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).